Clinical trial
Aspirin and a Potent P2Y12 Inhibitor Versus Aspirin and Clopidogrel Therapy in Patients Undergoing Elective Percutaneous Coronary Intervention for Complex Lesion Treatment (SMART-ATTEMPT)
NCT04014803 is registered in ClinicalTrials.gov with Samsung Medical Center as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- Aspirin and a Potent P2Y12 Inhibitor Versus Aspirin and Clopidogrel Therapy in Patients Undergoing Elective Percutaneous Coronary Intervention for Complex Lesion Treatment (SMART-ATTEMPT)
- Lead sponsor
- Samsung Medical Center
- Phase
- Phase 4
- Overall status
- Recruiting
- Start date
- January 13, 2020
- Completion date
- December 31, 2028
- Enrollment
- 3,500 (estimated)
- Sites
- 2
Conditions
As the registry lists them; a condition with its own page is linked.